News

Pfizer has reported revenues of $11.6b for the third-quarter of 2009, a 3% decrease compared with $12b in the year-ago quarter. Revenues for the quarter compared with the

MediWound has reported positive results from a pre planned interim analysis of a phase III trial for Debrase, an enzymatic debriding agent for burns. The company reported that

AFFiRiS’ phase I clinical studies of its two alzheimer’s vaccines AD01 and AD02 met primary endpoints and has demonstrated favourable safety and tolerability profiles. Reportedly, these results trigger

TechnoVax has received a three-year $2.9m SBIR phase II grant from the National Institutes of Health to further the development of its Virus-Like Particle (VLP)-based vaccine program. Reportedly,

Novartis’s Tasigna (nilotinib) met its primary endpoint in the first head-to-head comparison with Glivec (imatinib). The company said, Tasigna produced faster and deeper responses than Glivec when given

Pharmaco Group is extending its production line with six new drugs, which belong both to already existent and new therapeutic groups. Reportedly, Domestic pharmaceutical company keeps on developing

Novavax (Novavax) has initiated two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare. Avimex is providing

Novartis’ new phase II results show that the new therapy ACZ885 (canakinumab) is significantly more effective than an injectable corticosteroid at reducing pain and preventing recurrent attacks or

Beneo-Palatinit, a developer, manufacturer and marketer of Isomalt, has introduced galenIQ 981 excipient, which is said to offer ways to improve industrial processing, stability and shelf-life for drug